2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)

Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 | DOI:10.2807/1560-7917.ES.2024.29.7.2400076

Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research